Homework Help is Here – Start Your Trial Now!
Science
Biology
they argued that promoter switching may be correlated with cancer development and progression regardless of additional mutations. What evidence did they have to support this idea ?

they argued that promoter switching may be correlated with cancer development and progression regardless of additional mutations. What evidence did they have to support this idea ?

Biology: The Dynamic Science (MindTap Course List)
Biology: The Dynamic Science (MindTap Course List)
4th Edition
ISBN:9781305389892
Author:Peter J. Russell, Paul E. Hertz, Beverly McMillan
Publisher:Peter J. Russell, Paul E. Hertz, Beverly McMillan
Chapter16: Regulation Of Gene Expression
Section: Chapter Questions
Problem 1ITD
See similar textbooks
icon
Related questions
Question
100%
In Demircioglu et al (2019), the authors found that promoter switching for the ERBB2 gene was often associated with mutations in other known oncogenes and tumor suppresor genes. However, they argued that promoter switching may be correlated with cancer development and progression regardless of additional mutations. What evidence did they have to support this idea ? O They found that patients who had ERBB2 promoter switching but no other mutations in known oncogenes (OG) and tumor suppressor genes (TSG) carried many other mutations in genes that may have contributed to cancer progression and had not been identified as OG or TSG yet. O They saw that patients that showed promoter switching but did not have any other identifiable mutations had poorer prognosis than patients without promoter switching This was actually a discussion point; the authors did not have any experimental evidence to support their claim. O They treated all patients that showed promoter switching with the same drug and saw that they responded similarly O They found that patients with the mutations in the known oncogenes and tumor suppressor genes had overall worse prognosis than the general population
Transcribed Image Text:In Demircioglu et al (2019), the authors found that promoter switching for the ERBB2 gene was often associated with mutations in other known oncogenes and tumor suppresor genes. However, they argued that promoter switching may be correlated with cancer development and progression regardless of additional mutations. What evidence did they have to support this idea ? O They found that patients who had ERBB2 promoter switching but no other mutations in known oncogenes (OG) and tumor suppressor genes (TSG) carried many other mutations in genes that may have contributed to cancer progression and had not been identified as OG or TSG yet. O They saw that patients that showed promoter switching but did not have any other identifiable mutations had poorer prognosis than patients without promoter switching This was actually a discussion point; the authors did not have any experimental evidence to support their claim. O They treated all patients that showed promoter switching with the same drug and saw that they responded similarly O They found that patients with the mutations in the known oncogenes and tumor suppressor genes had overall worse prognosis than the general population
Expert Solution
steps

Step by step

Solved in 2 steps

SEE SOLUTIONCheck out a sample Q&A here
Blurred answer
Knowledge Booster
Genomic studies
Learn more about
Need a deep-dive on the concept behind this application? Look no further. Learn more about this topic, biology and related others by exploring similar questions and additional content below.
Similar questions
  • SEE MORE QUESTIONS
Recommended textbooks for you
Biology: The Dynamic Science (MindTap Course List)
Biology: The Dynamic Science (MindTap Course List)
Biology
ISBN:
9781305389892
Author:
Peter J. Russell, Paul E. Hertz, Beverly McMillan
Publisher:
Cengage Learning
SEE MORE TEXTBOOKS